For Labs, Specialty Practices & Value-Based Care
Ardia Health's AI engine reasons about clinical documentation to recover lost and wrongfully denied revenue — not just flagging errors, but explaining exactly why revenue was denied and generating evidence-backed recovery arguments.
Biomarkers: EGFR L858R mutation, PD-L1 75%
Recommendation: Osimertinib + Pembrolizumab combo
Payer: Medicare Advantage · Palmetto GBA
Denial: CO-50 Medical Necessity Not Established
Amount at Risk: $127.50
We're not a billing software. We're not an alert system. We're a clinical reasoning engine that understands payer logic from the inside.
Our engine reads clinical documentation, cross-references payer-specific LCD rules, and generates a mechanistic explanation for every denial — then builds the evidence-backed recovery argument.
12+ years at Cigna, UnitedHealth, Optum, and Teladoc. We know exactly how denial logic is constructed from the inside — giving us a unique advantage in defeating it.
We earn 15–20% of recovered revenue only when you succeed. No upfront cost. No implementation fees. ROI is visible within 30 days of deployment.
Manual appeals cost $118 and succeed 45% of the time. Ardia costs $2.50 and succeeds at 68–89% — a 47× cost reduction at nearly double the success rate.
The only platform combining genomic intelligence with reimbursement intelligence. We make precision medicine economically sustainable — MolDX, Z-codes, and 400+ PLA codes.
HIPAA-compliant from day one. AppExchange distribution to 150,000+ healthcare organizations. 60–70% faster development with 12 Salesforce certifications.
The RCM space is crowded with alerting tools, billing software, and generic AI. Ardia is the only platform that reasons, argues, and proves — built by people who designed the denial systems it defeats.
| Capability | Quest / LabCorp RCM | Generic AI (Olive, Waystar) | Traditional RCM Vendors | ⚡ Ardia Health |
|---|---|---|---|---|
| Clinical Reasoning (not just flagging) | ✗ | ✗ | ✗ | ✓ |
| Lab-Specific Denial Logic (LCD/NCD) | ⚠ Partial |
✗ | ✗ | ✓ |
| Auto-Generated Appeal Narratives | ✗ | ⚠ Generic only |
✗ | ✓ |
| Pharmacogenomics + MolDX Reimbursement | ✗ | ✗ | ✗ | ✓ |
| Zero-Risk Contingency Pricing | ✗ | ✗ | ⚠ Rare |
✓ |
| TX SB 1188 + TRAIGA Compliant by Design | ✗ | ✗ | ✗ | ✓ |
| Built by Former Payer Insiders (Cigna/UHC) | ✗ | ✗ | ✗ | ✓ |
Six automated steps. No manual review. No template letters. Clinical reasoning powered by AI at every stage — from raw denial data to payer-formatted appeal in under 90 seconds.
The AI in RCM market grows at 24% CAGR. Independent labs are completely unserved.
Pharmacogenomics, NGS, and molecular diagnostics are the fastest-growing — and highest-denial — segment of clinical lab testing. Ardia's MolecuIQ™ module is the only AI platform purpose-built for precision medicine reimbursement.
Full automation of MolDX DEX Z-code assignment and validation across all 28+ states. Zero manual Z-code lookup. Every molecular diagnostic claim checked for coverage before submission.
AI-managed PGx prior authorization across all major payers. Payer-specific rules, clinical evidence matching, and automated submission — reducing PGx prior auth denial rates by 60–80%.
NCCN guideline-to-diagnosis alignment checking for every NGS claim. LLM generates peer-reviewed clinical evidence citations in the appeal brief language payers respond to.
Ardia's proprietary genetic test-to-CPT mapping database covers 75,000+ genetic tests mapped to the correct billing codes — eliminating the ambiguity that causes most molecular diagnostic denials.
Every LCD/NCD/MolDX policy encoded as deterministic logic. The symbolic engine checks each precision medicine claim against applicable coverage criteria — 100% rule coverage, zero hallucinations.
LLM clinical reasoning generates payer-specific, NCCN-aligned appeal letters with peer-reviewed citations in under 90 seconds — what a specialist biller takes 2–4 hours to write manually.
This is Ardia's live denial intelligence dashboard — not a mockup. Click through it, run the 90-second trial, and see the AI reasoning engine in action.
Current Development Stage: Ardia is pre-revenue, seed stage, founded January 2026. The dashboard above is a functional prototype demonstrating the AI denial intelligence engine architecture. ToxIQ™ and MolecuIQ™ are in active Phase 1 development targeting Q2 2026 DFW pilot launch. AcoIQ™ and BehaviorIQ™ are on the 2027 roadmap.
Three products. Three screenshots. Built for independent labs, molecular diagnostics, and specialty practices. View full demo gallery →
ToxIQ™ + MolecuIQ™ Denial Intelligence Dashboard · Phase 1 Active · Open live interactive demo →
Each Ardia module targets a specific, high-complexity billing segment where AI delivers the highest value. Labs pay only a 15% success fee on recovered revenue — zero upfront cost.
Explore Ardia's live dashboard showing real-time denial analysis, MAC LCD cross-reference, and recovery narrative generation. Also available: mobile app demo for on-the-go claim management.
Our founders bring together two complementary areas of deep expertise — the technical architect who builds the AI and the payer insider who built the denial logic Ardia defeats.
Ardia Health Labs LLC · ardiahealthlabs.com · founders@ardiahealthlabs.com · Pre-Revenue · Seed Stage · Building on Google Cloud
Interactive dashboard showing real-time denial analysis, MAC LCD cross-reference, and recovery narrative generation.